Update on male hormonal contraceptive agents

Bibliography

• ZHANG G-Y, GU Y-Q, WANG X-H, CUT Y-G, BREMNER WJ: A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. I Clin. Endocrinol. Metab. (1999) 84:3642–3647.
   PubMed Web of Science ®Google Scholar
• LOOKINGBILL DP, DEMERS LM, WANG C, LEUNG A, RS,SANTEN RJ: Clinical and biochemical parameters of androgen action in normal healthy caucasian versus Chinese subjects.' Clin. Endocrinol. Metab. (1991) 72:1242–1248.
   Google Scholar
• SINHA HIKIM AP, WANG C, LUE Y, JOHNSON L, WANG, XH, SWERDLOFF RS: Spontaneous germ cell apoptosis in humans: evidence for ethnic differences in the susceptibility of germ cells to programmed cell death. j Clin. Endocrinol. Metab. (1998) 83:152–156.
   PubMed Web of Science ®Google Scholar
• SANTNER SJ, ALBERTSON B, ZHANG GY et al.: Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J. Clin. Endocrinol. Metab. (1998) 83:2104–2109.
   PubMed Web of Science ®Google Scholar
• ECKARDSTEIN SV, SCHMIDT A, KAMISCHKE A, SIMONI M, GROMOLL J, NIESCHLAG E: CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin. Endocrinol. (Ox!) (2002) 57:647–655.
   PubMed Web of Science ®Google Scholar
• McLACHLAN RI, ROBERTSON DM, PRUYSERS E et al.: Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment." an. Endocrinol. Metab (2004) 89:142–149.
   Google Scholar
• •Progestogens result in greater suppression than expected from the degree of gonadotropin suppression.
   Google Scholar
• Sixth Summit Meeting Consensus: recommendations for regulatory approval for hormonal male contraception. hat. Andra (2002) 25:375.
   Google Scholar
• McCULLAGH EP, McGURL FJ: Further observations on the clinical use of testosterone propionate. 1 Urol. (1939) 42:1265–1267.
   Google Scholar
• WORLD HEALTH ORGANISATIONTASK FORCE ON METHODS FOR REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet (1990) 336:955–959.
   PubMed Web of Science ®Google Scholar
• ••Major WHO-sponsored contraceptiveefficacy study.
   Google Scholar
• WORLD HEALTH ORGANISATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies. Int. J. Andra (1995) 18:157–165.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANISATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Feral Stern. (1996) 65:821–829.
   PubMed Web of Science ®Google Scholar
• ••Follow-up efficacy study to [9], including with oligozoospermia as well as azoospermia.
   Google Scholar
• SCHOMEYER T, WICKINGS EJ, FREISCHEM CW, NIESCHLAG E: Saliva serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol. (1983) 102:456–462.
   PubMedGoogle Scholar
• NIESCHLAG E, HOOGEN H, BOLK M,SCHUSTER H, WICKINGS EJ: Clinical with testosterone undecanoate for male control. Contraception (1978) 18:607–614.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, BREMNER WJ, COSTANTINO A, PAVANI A, M, FLAMINGI C: An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil. Stern. (1997) 68:844–850.
   PubMed Web of Science ®Google Scholar
• STUENKEL CA, DUDLEY RE, YEN SS:Sublingual administration of testosterone-hydroxypropyl-P-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. I Clin. Endocrinol. Metab. (1991) 72:1054–1059.
   PubMed Web of Science ®Google Scholar
• DOBS AS, HOOVER DR, CHEN MC, ALLEN R: Pharmacolkinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J. Clin. Endocrinol. Metab. (1998) 83:33–39.
   PubMed Web of Science ®Google Scholar
• KORBONITS M, SLAWIK M, D et al: A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. Clin. Endocrinol. Metab. (2004) 89:2039–2043.
   Google Scholar
• SWERDLOFF RS, WANG C, CUNNINGHAM G et al.: Long-term of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85:4500–4510.
   PubMed Web of Science ®Google Scholar
• WANG C, SWERDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal. Testosterone Gel Study Group. J. Clin. Endocrinol. Metab. (2000) 85:2839–2853.
   PubMed Web of Science ®Google Scholar
• BOCHTER D, VON ECKARDSTEIN S, VON ECKARDSTEIN A et al: Clinical of transdermal testosterone and oral for male contraception.. Endocrinol. Metab. (1999) 84:1244–1249.
   Web of Science ®Google Scholar
• HAIR WM, KITTERIDGE K, O'CONNOR DB, WU FC: A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. Clin. Endocrinol. Metab. (2001) 86:5201–5209.
   Google Scholar
• LI M, GUO S, FANG R, ZHANG Y: Pharmacological and clincal effects of testosterone undecanoate. New Drugs Clin. Remedies (1994) 279–281.
   Google Scholar
• ZHANG GY, GU YQ,WANG XH, CUI YG, BREMNER WJ: A study of injectable testosterone undecanoate in hypogonadal men. Andra (1998) 19:761–768.
   PubMed Web of Science ®Google Scholar
• GU YQ, WANG XH, XU D, PENG L, CHENG LF, HUANG MK, HUANG ZJ, ZHANG GY: A multicenter contraceptive study of injectable testosterone in healthy Chinese men.. Endocrinol. Metab. (2003) 88:562–568.
   Web of Science ®Google Scholar
• •The first large efficacy study of a longer-duration testosterone-only regime.
   Google Scholar
• VON ECKARDSTEIN S, E: Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a Phase II study. .1 Andra (2002) 23:419–425.
   Google Scholar
• KAMISCHKE A, VENHERM S, PLOGER D, VON ECKARDSTEIN S, NIESCHLAG E: Intramuscular undecanoate with enanthate in a clinical trial for male contraception. Clin. Endocrinol. Metab. (2000) 86:303–309.
   Google Scholar
• •Promising testosterone and progestogen preparations.
   Google Scholar
• KAMISCHKE A, PLOGER D, S, VON ECKARDSTEIN S, VON ECKARDSTEIN A, E: Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin. Endocrinol (Ox!) (2000) 53:43–52.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, ZHU H, CHENG L, BAIRD DT: Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants. Contraception (2002) 66:357–364.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN LM: Pharmacokinetics and pharmacodynamics of testosterone pellets in man. j Clin. Endocrinol Metab. (1990) 71:216–222.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, MACKEY MA, HOWE C, TURNER L, CONWAY AJ: An analysis of testosterone implants for androgen replacement therapy. Clin. Endocrinol (1997) 47:311–316.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN LM: Suppression of human spermatogenesis by testosterone implants. Clin. Endocrinol Metab. (1992) 75:1326–1332.
   Google Scholar
• •Dose sparing with long-acting testosterone preparation.
   Google Scholar
• McLACHLAN RI, McDONALD J, RUSHFORD D, ROBERTSON DM, GARRETT C, BAKER HWG: Efficacy and acceptability of testosterone implants, alone or in combination with a 5a-reductase inhibitor, for male contraception. Contraception (2000) 62:73–78.
   PubMed Web of Science ®Google Scholar
• BAGATELL CJ, BREMNER WJ: Androgens in men-uses and abuses. N Engl. J. Med. (1996) 334:707–714.
   PubMed Web of Science ®Google Scholar
• NEGRO-VILAR A: Selective androgen receptor modulators (SARMS): a novel approach to androgen therapy for the new millenium. I Clin. Endocrinol Metab. (1999) 84:3459–3462.
   PubMed Web of Science ®Google Scholar
• SMITH CL, O'MALLEY BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev (2004) 25:45–71.
   PubMed Web of Science ®Google Scholar
• KUMAR N, DIDOLKAR AK, MONDER C, BARDIN CW, SUNDARAM K: The biological activity of 7a-methyl- I9-nortestosterone is not in male reproductive tract as is that of testosterone. Endocrinology (1992) 130:3677–3683.
   PubMed Web of Science ®Google Scholar
• SUNDARAM K, KUMAR N, CW: 7a-methyl-nortestosterone (MENT) : the optimal androgen for male contraception. Ann. Med. (1993) 25:199–205.
   PubMed Web of Science ®Google Scholar
• KUMAR N, CROZAT A, LI F, CATTERALL JF, BARDIN CW, SUNDARAM K: 7a-methy1-19-nortestosterone, a synthetic androgen with high potency: structure-activity comparisons with other androgens. Steroid Biochem. MM. Biol. (1999) 71:213–222.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, MARTIN CW, KUNG et al: 7a-methy1-19-nortestosterone (MENT) maintains sexual behavior and mood in hypogonadal men. Clin. Endocrinol Metab. (1999) 84:3556–3562.
   Google Scholar
• NOE G, SUVISAARI J, MARTIN C et al: Gonadotrophin and testosterone suppression by 7a-methy1-19-nortestosterone acetate administered by subdermal implant to healthy men. Hum. Reprod. (1999) 14:2200–2206.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, WALLACE AM, SATTAR N, KUMAR N, SUNDARAM K: Evidence for tissue selectivity of the synthetic androgen 7a-methy1-19-nortestosterone in hypogonadal men. Clin. Endocrinol Metab. (2003) 88:2784–2793.
   Google Scholar
• •Investigation of a synthetic androgen with selective metabolism in hypogonadal men.
   Google Scholar
• LAMORTE A, KUMAR N, BARDIN CW, SUNDARAM K: Aromatization of 7a-methyl- I9-nortestosterone by human placental microsomes M vitro. J. Steroid Biorbem. MM. Biol. (1994) 48:297–304.
   PubMed Web of Science ®Google Scholar
• VON ECKARDSTEIN S, NOE G, BRACHE Vet al.: A clinical trial of 7a-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J. Clin. Endocrinol Metab. (2003) 88:5232–5239.
   Google Scholar
• KUUSI T, NIKKILA EA, TIKKANEN MJ, SIPINEN S: Effects of two progestins with different androgenic properties on hepatic endothelial lipase and high density lipoprotein2. Atherosclerosis (1985) 54:251–262.
   PubMed Web of Science ®Google Scholar
• MASCARENHAS L: Insertion and removalof Implanon. Contraception (1998) 58:79S–83S.
   Google Scholar
• CROXATTO HB, MAKARAINEN L: The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception (1998) 58:91S–97S.
   Google Scholar
• ANAWALT BD, HERBST KL, MATSUMOTO AM, MULDERS TM, COELINGH-BENNINK HJ, BREMNER WJ: Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil. Steil]. (2000) 74:707–714.
   PubMed Web of Science ®Google Scholar
• KINNIBURGH D, ZHU H, CHENG L, KICMAN AT, BAIRD DT, RA: Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum. Reprod. (2002) 17:1490–501.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, VAN DER SPUY ZM, DADA OA et al.: Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone. Hum. Reprod. (2002) 17:2869–77.
   Google Scholar
• ANDERSON RA, KINNIBURGH D, BAIRD DT: Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J. Clin. Endocrinol Metab. (2002) 87:3640–3649.
   PubMed Web of Science ®Google Scholar
• •Use of etonogestrel implants with testosterone pellets.
   Google Scholar
• BEBB RA, ANAWALT BD, CHRISTENSEN RB, PAULSEN CA, BREMNER WJ, MATSUMOTO AM: Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J. Clin. Endocrinol Metab. (1996) 81:757–762.
   PubMed Web of Science ®Google Scholar
• ANAWALT BD, BEBB RA, WJ, MATSUMOTO AM: A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J. Andra (1999) 20:407–414.
   PubMed Web of Science ®Google Scholar
• •Exploration of dose-response relationship of levonorgestrel with TE.
   Google Scholar
• GONZALO IT, SWERDLOFF RS, NELSON AL et al.: Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable. Clin. Endocrinol Metab. (2002) 87:3562–3572.
   Google Scholar
• •Comparison of two androgen/progestogen regimes using LNG implants.
   Google Scholar
• GAO E, LIN C, GUI Y LI L, HE C: effects of Sino-implant plus testosterone undecanoate (TU) on spermatogenesis in Chinese men. Reproduction it- Contraception (1999) 10:98–105.
   PubMedGoogle Scholar
• WORLD HEALTH ORGANISATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil. Steril (1993) 60:1062–1068.
   PubMed Web of Science ®Google Scholar
• MELO JF, COUTINHO EM: Inhibitionof spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate. Contraception (1977) 15:627–635.
   PubMed Web of Science ®Google Scholar
• ALVAREZ-SANCHEZ F, FAUNDES A, BRACHE V, LEON P: Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate. Contraception (1977) 15:635–648.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, HOWE CJ, TURNER L, MACKEY MA: Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. Clin. Endocrinol Metab. (1996) 81:4113–4121.
   Google Scholar
• •Demonstration of testosterone dose-sparing effect of a progestogen.
   Google Scholar
• TURNER L, CONWAY AJ, JIMENEZ M, LIU PY, FORBES E, McLACHLAN RI, HANDELSMAN DJ: Contraceptive efficacy of a depot progestin and androgen combination in men. J. Clin. Endocrinol Metab. (2003) 88:4659–4667.
   PubMed Web of Science ®Google Scholar
• •An important efficacy study of a promising combination of hormones.
   Google Scholar
• MOELOEK N, PUJIANTO DA, AGUSTIN R, ARSYAD KM, WALUYO P, PRIYUGIHARTA Y, MBIZVO MT: Achieving azoospermia by injections of testosterone undecanoate alone or combined with depot medroxyprogesterone acetate in Indonesian men (Jakarta centre study). Proceeding of the 7th International Congress of Andrology Montreal, Canada (2001) poster 1/2–133.
   Google Scholar
• GU YQ, TONG JS, MA DZ et al.: Malehormonal contraception: effects of of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. J. Clin. Endocrinol Metab. (2004) 89:2254–62.
   PubMed Web of Science ®Google Scholar
• LEMUS AE, ENRIQUEZ J, GARCIA GA,GRILLASCA I, PEREZ-PALACIOS G: 5a-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency. J. Steroid Biochem. Ma Biol. (1997) 60:121–129.
   PubMed Web of Science ®Google Scholar
• GUERIN JF, ROLLET J: Inhibition of spermatogenesis in men using various combinations of oral progestogens and percutaneous or oral androgens. Int. J. Andra (1988) 11:187–199.
   PubMed Web of Science ®Google Scholar
• KAMISCHKE A, HEUERMANN T, KRUGER K et al.: An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. Clin. Endocrinol Metab. (2002) 87:530–539.
   Google Scholar
• •This combination has a great potential for a single injectable administration.
   Google Scholar
• MERIGGIOLA MC, BREMNER WJ, PAULSEN CA et al.: A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive../. Clin. Endocrinol Metab. (1996) 81:3018–3023.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the high efficacy of oral CPA.
   Google Scholar
• MERIGGIOLA MC, BREMNER WJ, COSTANTINO A, DI CINTIO G, FLAMIGNI C: Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum. Reprod. (1998) 13:1225–1229.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, COSTANTINO A, CERPOLINI S et al.: Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. I Clin. Endocrinol Metab. (2003) 88:5818–5826.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, BREMNER WJ, COSTANTINO A et al.: Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J. Clin. Endocrinol Metab. (2002) 87:2107–2113.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E, BEHRE HM, WEINBAUER GF: Hormonal male contraception: a real chance? In: Spermatogenesis-Fertilization-Contraception. Molecular, cellular and endocrine events M male reproduction. E Nieschlag, UF Halbernich (Eds), Springer, Heidelberg, Germany (1992):477–501.
   Google Scholar
• BEHRE HM, NASHAN D, HUBERT W, NIESCHLAG E: Depot gonadotrophin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. I. Gin. Endocrinol Metab. (1992) 74:84–90.
   PubMed Web of Science ®Google Scholar
• BHASIN S, BERMAN N, RS: Follicle-stimulating hormone (FSH) escape during chronic gonadotrophin-releasing hormone (GnRH) agonist and testosterone treatment. J. Andra (1994) 15:386–391.
   PubMed Web of Science ®Google Scholar
• PAVLOU SN, BREWER K, FARLEY MG et al.: Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J. Endocrinol Metab. (1991) 73:1360–1369.
   PubMed Web of Science ®Google Scholar
• TOM L, BHASIN S, SALAMEH W et al.:Induction of azoospermia in normal men with combined Nal-Glu gonadotrophin releasing hormone antagonist and testosterone enanthate. I Clin. Endocrinol Metab. (1992) 75:476–483.
   PubMed Web of Science ®Google Scholar
• SWERDLOFF RS, BAGATELL CJ, WANG C, ANAWALT BD, BERMAN N, STEINER B, BREMNER WJ: Suppression of spermatogenesis in man induced by Nal-Glu gonadotrophin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. I Gin. Endocrinol Metab. (1998) 83:3527–3533.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, KLIESCH S, LEMCKE B, VON ECKARDSTEIN S, E: Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum. Reprod. (2001) 16:2570–2577.
   PubMed Web of Science ®Google Scholar
• •Demonstration of effectiveness of a clinically available GnRH antagonist.
   Google Scholar
• TOMERA K, GLEASON D, M et al.: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. [Ira (2001) 165:1585–1589.
   Google Scholar
• ERB K, PECHSTEIN B, SCHUELER A,ENGEL J, HERIVIANN R: Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist in healthy men-a first-dose-in- study. Clin. Phannacol Ther: (2000) 67:660–669.
   PubMed Web of Science ®Google Scholar
• HERBST KL, ANAWALT BD, JK, BREMNER WJ: Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J. Clin. Endocrine]. Metab. (2002) 87:3215–20.
   PubMed Web of Science ®Google Scholar
• HARA T, ARAKI H, KUSAKA M et al.:Suppression of a pituitary-ovarian axis by oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys. Clin. Endocrine]. Metab. (2003) 88:1697–704.
   PubMed Web of Science ®Google Scholar
• REN D, NAVARRO B, PEREZ G et al.:A sperm ion channel required for sperm motility and male fertility. Nature (2001) 413:603–609.
   PubMed Web of Science ®Google Scholar
• BRETON S, SMITH PJS, LUI B, BROWN D: Acidification of the male tract by a proton-pumping (H±)-ATPase. Nat. Med. (1996) 2:470–472.
   PubMed Web of Science ®Google Scholar